SCHEMBL3344565

SCHEMBL3344565

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2S(C)(=O)=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
STK17A Q9UEE5 2/20 0.41
PAK1 Q13153 1/20 0.40
KDM4E B2RXH2 1/20 0.40
SYK P43405 2/20 0.40
CSNK2A1 P68400 4/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
P2RY12 Q9H244 1/20 0.39
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
STK17B O94768 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
GLP1R P43220 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13311563 0.89 NPC1 (0.45) FGFR1EGFRERBB2STK17APAK1
SCHEMBL13348282 0.88 CSNK2A1 (0.49) EGFRSTK17ACSNK2A1ABL1BCR
SCHEMBL3342145 0.87 CDK2 (0.40) FGFR1KDM4ESYKMEN1THRB
SCHEMBL13348125 0.85 CCNA2 (0.43) FGFR1EGFRERBB2STK17APAK1
SCHEMBL3449089 0.85 STK17A (0.44) FGFR1EGFRERBB2STK17APAK1
SCHEMBL3449014 0.84 SYK (0.47) FGFR1EGFRERBB2STK17APAK1
SCHEMBL3448587 0.84 STK17A (0.50) FGFR1EGFRERBB2STK17APAK1
SCHEMBL3449108 0.84 P2RY12 (0.46) FGFR1PAK1P2RY12
SCHEMBL3448523 0.83 P2RY12 (0.43) FGFR1EGFRERBB2STK17APAK1
SCHEMBL3448849 0.83 SYK (0.49) FGFR1EGFRERBB2STK17APAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD FGFR1 3917/4885EGFR 2771/4885ERBB2 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.